Private: Fullwidth Portfolio Post


Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ... Read More


In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback ... Read More


CADTH is currently updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. To help with this initiative, CADTH is inviting interested stakeholders to provide input. These guidelines detail best practices for conducting economic evaluations and are used to standardize and facilitate economic evaluations while ... Read More


As requested by stakeholders, the deadline for the following CADTH calls for stakeholder input has been extended to November 9, 2015 at 5:00 p.m. EST: CDR Update – Issue 111 CADTH Consultation: Revisions to the Common Drug Review Procedure Invites stakeholder comments and feedback on the following proposed revisions to the Procedure ... Read More


Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately. Please note that for ... Read More


CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month. Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation. For ... Read More


Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto. Please note the new main telephone and fax ... Read More


Category 1 requirements for products that undergo a tailored CDR review have been revised. Submissions for new combination products (funded components) and new combination products designated by CADTH to undergo a tailored CDR review will require completion of the revised New Combination Product Submission Template.  This revised template ... Read More


CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More


Pilot Extension for Individual Patient Input to the Common Drug Review The Common Drug Review (CDR) is extending its pilot to receive patient input submissions from individual patients and caregivers until August 3, 2015. Pilot Extension for Patient Input for Therapeutic Reviews CADTH implemented a pilot process for receiving patient input submissions for ... Read More